

Lead Generation of DLL3-ADC for the Treatment of Small Cell Lung Cancer



ONCOLOGY	Lead
Product Type	Antibody-Drug Conjugate
Indication	Small-Cell Lung Cancer (SCLC) & Other Solid Cancers
Target	Delta-Like Ligand 3 (DLL3)
MoA(Mechanism of Action)	DNA alkylation: Binding to cell surface antigen → Endocytosis → Lysosomal degradation → Active payload release → DNA alkylation → Cell death
Competitiveness	<ul style="list-style-type: none"> • Self-immolative OHPAS linker : high stability in circulation and fast release of payload in the targeted tissues. • Payload modification technology (PMT) : Reduced non-specific uptake in normal cells → Improved therapeutic index. • Site specific conjugation of drug-linker : Improved homogeneity of DAR, simplified quality control with high reproducibility.
Development Stage	Lead
Route of Administration	Parenteral-Intravenous